Stockscreener 앱 받기
1.33
8.13%
0.10
시장 영업 전:
1.35
0.02
+1.50%
전일 마감가:
$1.23
열려 있는:
$1.25
하루 거래량:
3.33M
Relative Volume:
1.38
시가총액:
$109.42M
수익:
$65,300
순이익/손실:
$-84.95M
주가수익비율:
-0.688
EPS:
-1.9332
순현금흐름:
$-88.92M
1주 성능:
-2.21%
1개월 성능:
+17.70%
6개월 성능:
-24.43%
1년 성능:
-32.83%
1일 변동 폭
$1.22
$1.34
1주일 범위
$1.20
$1.445
52주 변동 폭
$1.03
$2.9789
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
명칭
Inovio Pharmaceuticals Inc
전화
(858) 410-3134
주소
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.33 | 101.20M | 65,300 | -84.95M | -88.92M | -1.9332 |
VRTX
Vertex Pharmaceuticals Inc
|
433.54 | 109.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
642.59 | 68.12B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
816.22 | 50.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.51 | 39.85B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.73 | 31.96B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-09 | 개시 | Piper Sandler | Overweight |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2024-01-25 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-11-09 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-11-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-19 | 재개 | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-12-29 | 재개 | Jefferies | Hold |
| 2021-09-10 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-06-24 | 개시 | Jefferies | Hold |
| 2021-03-23 | 개시 | BofA Securities | Neutral |
| 2021-02-12 | 개시 | Oppenheimer | Outperform |
| 2020-11-17 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-11-10 | 업그레이드 | ROTH Capital | Sell → Neutral |
| 2020-09-28 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-07-01 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-06-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-21 | 개시 | The Benchmark Company | Buy |
| 2020-04-30 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-03-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | 개시 | ROTH Capital | Buy |
| 2018-02-15 | 재확인 | Maxim Group | Buy |
| 2017-10-18 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-06 | 개시 | Citigroup | Buy |
| 2017-06-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | 재확인 | Maxim Group | Buy |
| 2017-03-16 | 업그레이드 | Maxim Group | Hold → Buy |
| 2017-03-16 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
모두보기
Inovio Pharmaceuticals Inc 주식(INO)의 최신 뉴스
INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia Trial - Stocktwits
ApolloBio reports positive phase 3 results for VGX-3100 in China - Investing.com UK
Positive Phase 3 Results for Inovio (INO) Partnered VGX-3100 in China - GuruFocus
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio (NASDAQ: INO) director awarded RSUs and 41,800 options - Stock Titan
[Form 4] INOVIO PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Inovio (NASDAQ: INO) grants RSUs and stock options to director Ann Calby Miller - Stock Titan
Equity grants to Inovio (NASDAQ: INO) director David Weiner disclosed - Stock Titan
Inovio (NASDAQ: INO) director receives RSUs and stock options grant - Stock Titan
Inovio (NASDAQ: INO) director granted 34,200 RSUs and 41,800 options - Stock Titan
INOVIO (INO) Chief Scientific Officer reports RSU vesting, tax withholding and new stock option awards - Stock Titan
Inovio (INO) CMO granted RSUs and 46,876 stock options at $1.73 - Stock Titan
Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China - PR Newswire
Inovio (INO) CFO granted stock options, RSUs and reports RSU vesting - Stock Titan
Inovio (NASDAQ: INO) CEO receives new RSUs and options as shares withheld for taxes - Stock Titan
Inovio Shareholders Endorse Governance Changes and Leadership - TipRanks
Inovio Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Inovio (NASDAQ: INO) overhauls board roles and wins approval on all 2026 shareholder proposals - Stock Titan
Inovio Pharmaceuticals, Inc. Stock Alert: INO Stockholders Who L - GuruFocus
$Moderna (MRNA.US)$ $Inovio Pharmaceuticals (INO.US)$ $3M (MMM.US)$ - Moomoo
Earnings call transcript: Inovio beats Q1 2026 EPS forecast but stock slips - Investing.com UK
Earnings call transcript: Inovio beats Q1 2026 EPS forecast but stock slips By Investing.com - Investing.com South Africa
Inovio Stock Price Today | NASDAQ: INO Live - Investing.com
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Inovio (NASDAQ: INO) CEO nets shares from RSU vesting and tax withholding - Stock Titan
Inovio Pharmaceuticals (INO) CFO exercises 4,771 RSUs and has 2,571 shares withheld for taxes - Stock Titan
INOVIO (NASDAQ: INO) CSO settles RSUs, shares withheld for tax - Stock Titan
INOVIO (NASDAQ: INO) CMO vests RSUs and withholds shares for taxes - Stock Titan
Inovio Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:INO) 2026-05-16 - Seeking Alpha
INO Should I Buy - Intellectia AI
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2026 Earnings Call Transcript - Insider Monkey
Highbridge reports 6.19M warrant‑issued shares in Inovio (INO) - Stock Titan
Investigation Alert: Investors who hold shares of Inovio - openPR.com
INOVIO Shares Drop 10% After Discounted $25 Million Public Offering - MSN
Inovio Pharmaceuticals stock (US45773H2013): Q1 2026 results and INO-3107 FDA review - AD HOC NEWS
Inovio: All Eyes On INO-3107 As Binary FDA Decision Looms (NASDAQ:INO) - Seeking Alpha
Q1 2026 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Inovio Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
INOVIO Reports First Quarter 2026 Financial Results and Recent B - GuruFocus
Inovio Pharmaceuticals Inc (INO) Q1 2026 Earnings Call Highlights: Progress and Challenges in Advancing INO-3107 - GuruFocus
Inovio outlines cash runway into Q1 2027 as INO-3107 targets October 30, 2026 PDUFA date - MSN
Inovio and Fossil Q1 results highlight strategic progress - MSN
Salt Lake City Topic INOVIO PHARMACEUTICALS, INC. | News, Weather, Sports, Breaking News - KMYU
Earnings call transcript: Inovio’s Q1 2026 highlights clinical progress, stock rises 2.84% - Investing.com UK
Inovio Pharmaceuticals (INO) Q1 2026 Earnings Report Highlights Progress and Cash Position - GuruFocus
Is Inovio Pharmaceuticals (INO) Still 545.2% Overvalued After Q1 - GuruFocus
Inovio (INO) Q1 2026 Earnings Call Transcript - AOL.com
Full Transcript: Inovio Pharmaceuticals Q1 2026 Earnings Call - Benzinga
Inovio Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Inovio’s Q1 2026 highlights clinical progress, stock rises 2.84% By Investing.com - Investing.com South Africa
Inovio Pharmaceuticals Inc (INO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.72%
0.63%
자본화:
|
볼륨(24시간):